establishing a committee to study the feasibility of establishing experimental treatment centers in New Hampshire and the oversight thereof.
What changed between versions
The entire new chapter 126-ZZ (Experimental Treatment Centers) was removed, including definitions for eligible patient, experimental treatment, experimental treatment center, qualified medical institution, and other protected access.
A study committee was established consisting of 2 senators (one minority) and 3 house members (one minority) to research the feasibility of experimental treatment centers in New Hampshire.
The authorization for drug/biologic/device manufacturers or treatment centers to provide investigational products to eligible patients without FDA approval was removed.
The committee is directed to determine what oversight would be needed from DHHS, the Bureau of Consumer Protection, and the Office of Professional Licensure, and to solicit testimony from regulators, current operators, other states' oversight bodies, FDA experts, and cGMP manufacturing experts.
All patient eligibility criteria (physician recommendation, written informed consent requirements, discussion of alternatives and outcomes) were removed.
The committee must report its findings and any legislative recommendations to the president of the senate, speaker of the house, both clerks, the governor, and the state library by November 1, 2026.